Technology Platforms

The company has established a comprehensive platform of antibody drug discovery, aiming to build a globally competitive pipeline of innovative large-molecule drugs. Leveraging a seasoned antibody R&D team, cutting-edge technologies, and integrated artificial intelligence (AI) capabilities, the platform independently conducts end-to-end research from scratch—encompassing target discovery, early antibody discovery and screening, bispecific/multispecific antibody design and optimization, in vitro bioactivity assays, in vivo efficacy and pharmacokinetic (PK) studies, and druggability assessment. To date, several internally developed bispecific/multispecific antibody candidates targeting oncology and autoimmune diseases have advanced to cell line development and Investigational New Drug (IND) - enabling stages. These molecules exhibit clear best-in-class (BIC) or first-in-class (FIC) potential, addressing areas of highly unmet medical needs.

As an all-encompassing, high-efficiency antibody drug discovery platform to integrate discovery, innovation, and application, it is supported by an R&D team with extensive expertise across multiple antibody modalities—including bispecific/multispecific antibodies, T-cell engagers (TCEs), antibody-drug conjugates (ADCs), and nanobodies. By harnessing the unique characteristics and advantages of each format, coupled with profound insights into target biology and disease mechanisms, the team drives differentiated innovation throughout the entire drug development process, with a steadfast focus on delivering real clinical benefits.

Integrating the company's commercialization strengths, the platform enables the translation of antibody therapeutics from original innovation to commercialization. This aligns with the company’s vision: to rapidly bring breakthrough therapies with high clinical value to patients worldwide.

As an innovative class of precision medicines, oligonucleotide drugs—represented by antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs)—offer distinct advantages, including access to a broad range of disease targets, high target specificity, durable pharmacological effects, and modular design. These attributes contribute to a higher success rate in discovery and clinical translation. In recent years, the therapeutic application of oligonucleotide drugs has expanded from rare genetic disorders to common chronic diseases, establishing them as a promising third pillar of modern medicine alongside traditional small molecules and monoclonal antibodies.

The company is dedicated to build up a fully integrated, proprietary R&D platform for oligonucleotide therapeutics, built upon four core capabilities: sequence design, chemical modification, targeted delivery, and CMC (Chemistry, Manufacturing, and Controls). By integrating AI-driven predictive algorithms with high-throughput experimental screening, the platform enables rapid identification and iterative optimization of lead candidates. The company continues to advance novel chemical modifications and next-generation delivery systems to enhance the stability, tissue selectivity, and overall druggability of its therapeutic pipeline. Guided by unmet clinical needs, the company focuses on high-demand chronic disease—including cardiovascular, respiratory, and kidney indications—and is committed to developing highly effective and safe oligonucleotide therapies, to deliver more efficacious, safer, and more convenient treatment options for patients worldwide.